Last reviewed · How we verify
Met097 (met097)
MET097, developed by Pfizer Inc., is a marketed drug for treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. It has generated $21.2B in revenue. The drug's mechanism is not specified on Wikipedia. MET097 has 8 clinical trials and 0 publications. Its key indications include treating adult patients with NSCLC harboring EGFR exon 20 insertion mutations. The commercial significance of MET097 is substantial, given its revenue and market presence. However, pipeline developments for similar treatments may impact its future prospects.
At a glance
| Generic name | met097 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Not specified |
| Target | Not specified |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
- Treatment of adult patients with non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion mutation
Common side effects
Drug interactions
- Warfarin
- Aspirin
- Clopidogrel
- Pentoxifylline
- Dipyridamole
- Ticlopidine
- Alteplase
- Urokinase
- Streptokinase
- Tenecteplase
- Reteplase
- Abciximab
Key clinical trials
- A Study to Learn How the Study Medicine Called PF-08653944 is Taken up Into the Blood in Adults With Overweight or Obesity. (PHASE1)
- Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM (PHASE2)
- A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight (PHASE2)
- A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight (PHASE2)
- A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) (PHASE3)
- A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes (PHASE1, PHASE2)
- This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Met097 CI brief — competitive landscape report
- Met097 updates RSS · CI watch RSS
- Pfizer portfolio CI